In the last trading session, 1.3 million Legend Biotech Corp ADR (NASDAQ:LEGN) shares changed hands as the company’s beta touched 0.12. With the company’s per share price at $30.07 changed hands at $0.96 or 3.30% during last session, the market valuation stood at $5.53B. LEGN’s last price was a discount, traded about -102.43% off its 52-week high of $60.87. The share price had its 52-week low at $27.34, which suggests the last value was 9.08% up since then.
Analysts gave the Legend Biotech Corp ADR (LEGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.23. If we narrow down to specifics, the data shows that 0 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LEGN as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight.
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Instantly LEGN was in green as seen at the end of in last trading. With action -3.25%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -7.59%, with the 5-day performance at -3.25% in the red. However, in the 30-day time frame, Legend Biotech Corp ADR (NASDAQ:LEGN) is -6.73% down.
The consensus price target for the stock as assigned by Wall Street analysts is 75, meaning bulls need an upside of 59.91% from its current market value. According to analyst projections, LEGN’s forecast low is 75 with 75 as the target high. To hit the forecast high, the stock’s price needs a -149.42% plunge from its current level, while the stock would need to soar -149.42% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.79%. The 2025 estimates are for Legend Biotech Corp ADR earnings to increase by 11.62%.
LEGN Dividends
Legend Biotech Corp ADR is expected to release its next quarterly earnings report in June.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.292% or 11.49 million shares worth $508.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were AIM Investment Fd.s -Invesco Developing Markets Fd. and Fidelity Select Portfolios-Health Care Portfolio . With 2.96 shares estimated at $89.13 million under it, the former controlled 1.61% of total outstanding shares. On the other hand, Fidelity Select Portfolios-Health Care Portfolio held about 1.52% of the shares, roughly 2.8 shares worth around $84.2 million.
